Global Proteinuria Therapeutics Market – Dynamics
The increase in prevalence of chronic kidney disease, a major cause of proteinuria is expected to drive growth of the global proteinuria therapeutics market. For instance, according to the Centers for Disease Control and Prevention, in March 2021, over one in seven, accounting for 37 million people (15% of the adults), are estimated to have chronic kidney disease in the U.S. Moreover, according to the same source, Chronic kidney disease was found to be more prevalent in people aged 65 years or older (38%) compared to people aged 45–64 years (12%) or 18-44 years (6%).
The increasing clinical development of drugs for the treatment of chronic kidney disease and proteinuria is expected to boost global proteinuria therapeutics market growth. For instance, on June 06, 2021, Novartis, a global healthcare company, revealed their Phase II primary endpoint data demonstrating that investigational ‘iptacopan’ reduced protein in the urine (proteinuria), a key risk predictor associated with progression of kidney failure. Iptocan is a first-in-class, oral, targeted factor B inhibitor, which also showed a stabilizing kidney function in patients with IgA nephropathy.
The rising mergers, agreements, and acquisitions by market players are expected to propel growth of the global proteinuria therapeutics market over the forecast period. For instance, on January 10, 2020, Chinook Therapeutics Inc., a biotechnology firm focused on developing precision medicines for kidney diseases, announced a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide exclusive rights to ‘atrasentan’, an endothelin receptor antagonist. Atrasentan is being developed for the treatment of primary glomerular diseases, which are characterized by proteinuria. These factors are expected to support global proteinuria therapeutics market growth over the forecast period.
Proteinuria Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients